etoposide + carboplatin + vincristine + siβ3

This is an experimental oncology drug regimen combining three established anticancer agents (etoposide, carboplatin, and vincristine) with siβ3, which is not a standard oncology drug but likely refers to a small interfering RNA (siRNA) targeting β3 integrin (ITGB3). Notably, only "etoposide + carboplatin + vincristine" (CEV or similar combinations) are established in clinical practice for cancers such as small-cell lung cancer, where they act synergistically to inhibit tumor growth through distinct mechanisms: etoposide inhibits topoisomerase II, carboplatin is a platinum-based DNA crosslinker, and vincristine is a microtubule inhibitor[1][3]. The siβ3 component is not reported in clinical literature or widely recognized as part of any established anticancer regimen; its inclusion suggests a research or investigational context, possibly aiming to enhance efficacy or overcome resistance by targeting β3 integrin-mediated pathways, but no clinical data or published trials for this specific four-drug combination exist.